Valneva now has three commercialized vaccines, and a Lyme disease candidate in Phase 3. Philip quizzes CEO Thomas Lingelbach about everything. They also discuss the current political turbulence with vaccines, especially in the US, and how it is impacting the industry.⭐️ ABOUT THE SPEAKERA veteran in the development of more than ten vaccines, Thomas has spent over 30 years in the vaccine space and has served in senior roles at the companies Intercell, Novartis and Chiron. Thomas was with Intercell since 2006 and was the CEO when the company merged with Vivalis to form Valneva in 2013.🔗 LINKS MENTIONED

• Valneva’s website - https://valneva.com/
• Valneva’s Half Year 2025 Financial Results - https://valneva.com/press-release/valneva-reports-half-year-2025-financial-results-and-provides-corporate-updates/
• Lovisa Afzelius, Flagship Pioneering 🇸🇪 | Company building, AI | E24https://flot.bio/episode/lovisa-afzelius-flagship-pioneering/

📜 TRANSCRIPT

Read the full transcript here: https://flot.bio/episode/thomas-lingelbach-valneva-vaccines/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US

• Newsletter: http://eepurl.com/h_fnmH
• LinkedIn: https://www.linkedin.com/company/flot-bio/
• X (Twitter): https://x.com/FlotBio

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ Timestamps

• [00:00:00] Intro
• [00:03:09] Duck cell vaccines
• [00:04:55] The grandpa of French and Austrian biotech
• [00:15:09] Products for chikungunya, Japanese encephalitis and cholera
• [00:22:04] Valneva and Pfizer’s Lyme disease vaccine
• [00:29:46] Navigating US anti-vaccine turbulence
• [00:33:33] The stormy biotech investment market
• [00:36:32] Thomas Lingelbach talks financials
• [00:39:46] Quick-fire questions